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Abstract: BACKGROUND The present study sought to evaluate the incidence of cerebrovascular events
in a large cohort of patients with Brugada syndrome (BrS) analysing possible predictors, clinical char-
acteristics and prognosis of cardioembolic events secondary to atrial fibrillation. METHODS A total of
671 consecutive patients (age 42.1 ± 17.0 years; men 63%) with a diagnosis of BrS were retrospectively
analysed over a mean follow-up period of 10.8 ± 5.5 years. The diagnosis of ischemic stroke was made
according to the AHA/ASA guidelines using computed tomography (CT) and angio-CT in the emergency
department. RESULTS Among 671 patients with BrS, 79 (11.8%) had atrial fibrillation. The incidence
of cardioembolic stroke in patients with BrS and atrial fibrillation was 13.9% (11 events). These patients
had a low CHA2DS2Vasc score (82%, 0 and 1). Patients with transient ischemic attack/stroke were more
frequently asymptomatic (91 vs. 25%; P < 0.0001) and older (59.4 ± 11.2 vs. 43.9 ± 16.7; P = 0.004)
as compared with those without cerebrovascular events. CONCLUSION The incidence of cardioembolic
stroke in patients with BrS and atrial fibrillation was unexpectedly high. The cerebrovascular accidents
were often the presenting clinical manifestation and were significantly associated with asymptomatic
atrial fibrillation and older age. CHADS2 and CHA2DS2Vasc scores did not predict the unexpectedly
high risk of thromboembolic events in this group of patients. The use of more invasive diagnostic tools
might be useful in order to increase the rate of atrial fibrillation detection.
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Background The present study sought to evaluate the
incidence of cerebrovascular events in a large cohort of
patients with Brugada syndrome (BrS) analysing possible
predictors, clinical characteristics and prognosis of
cardioembolic events secondary to atrial fibrillation.
Methods A total of 671 consecutive patients (age
42.1W17.0 years; men 63%) with a diagnosis of BrS were
retrospectively analysed over a mean follow-up period of
10.8W5.5 years. The diagnosis of ischemic stroke wasmade
according to the AHA/ASA guidelines using computed
tomography (CT) and angio-CT in the emergency
department.
Results Among 671 patients with BrS, 79 (11.8%) had atrial
fibrillation. The incidence of cardioembolic stroke in
patients with BrS and atrial fibrillation was 13.9% (11
events). These patients had a low CHA2DS2Vasc score
(82%, 0 and 1). Patients with transient ischemic attack/
stroke were more frequently asymptomatic (91 vs. 25%;
P<0.0001) and older (59.4W11.2 vs. 43.9W16.7; PU0.004)
as compared with those without cerebrovascular events.
Conclusion The incidence of cardioembolic stroke in
patients with BrS and atrial fibrillation was unexpectedly
high. The cerebrovascular accidents were often the
presenting clinical manifestation and were significantly
associated with asymptomatic atrial fibrillation and older
age. CHADS2 and CHA2DS2Vasc scores did not predict the
unexpectedly high risk of thromboembolic events in this
group of patients. The use of more invasive diagnostic tools
might be useful in order to increase the rate of atrial
fibrillation detection.
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Introduction
Brugada syndrome (BrS) is an inheritable syndrome
characterized by coved-type ST-segment elevation in
the right precordial leads (V1 through V3) and increased
risk of ventricular fibrillation/sudden cardiac death (SCD)
in the absence of structural heart disease.1 The preva-
lence of atrial fibrillation in patients with BrS is highly
variable ranging from 25 to 39% in older studies1–3 and
from 9 to 19%4–6 in the most recent studies. Of note, the
initial report on the Brugada syndrome reported that two
out of eight affected individuals had paroxysmal atrial
fibrillation1; one of them experienced episodes of atrial
fibrillation soon after birth.
The incidence of cerebrovascular events such as transient
ischemic attack (TIA) and stroke related to thromboem-
bolism in patients with BrS and atrial fibrillation has not
been investigated yet. As a matter of fact, the predictive
value of the CHA2DS2Vasc score for assessing the risk of
cerebrovascular thromboembolic events in this popula-
tion is still unknown.
The present study sought to evaluate the incidence of
cerebrovascular events in a large cohort of patients with
BrS analysing possible predictors, clinical characteristics




Since 1992, all consecutive patient diagnosis with BrS
have been included in a registry and followed in a
prospective fashion. The ethics committee of the Uni-
versiteit Ziekenhuis Brussel – Vrije Universiteit Brussel
approved all aspects of the registry. A total of 671 conse-
cutive patients with a diagnosis of BrS from the Heart
Rhythm Management Centre, Universitair Ziekenhuis
Brussel were included. All patients showed a typical
electrocardiographic Brugada pattern with or without a
sodium channel blocker challenge, as previously
reported.7 Underlying structural cardiac abnormalities
were excluded in all patients with noninvasive methods
(echocardiogram, stress test and nuclear magnetic reso-
nance) or invasive methods (coronary angiography, left
and right ventriculography) used at the discretion of the
treating physician. Informed consent was obtained from
all patients, and clinical data, including data on age, sex,
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family history of SCD, history of syncope episodes,
history of ventricular fibrillation episodes, and ventricular
fibrillation induction during an electrophysiological study
were obtained from patient records. Importantly, many
drugs have been reported to induce the type 1 BrS
pattern and/or (fatal) arrhythmias in BrS patients. There-
fore, patients with BrS were recommended not to use
these drugs or to use them only under controlled condi-
tions.8
Ajmaline challenge
Ajmaline (1mg/kg) was administered intravenously
over a 5-min period to unmask the diagnostic ECG
pattern of BrS in case of a nondiagnostic baseline
electrocardiogram and suspicions of Brugada syndrome.
The test was considered positive for BrS only if a
coved-type ECG pattern was documented in one right
precordial lead (V1–V3). An Ajmaline challenge was
performed in all patients with a history of aborted
sudden death or family history of aborted sudden death,
in patients with history of syncope or presyncope, in
patients with supraventricular arrhythmias, in all new
diagnoses of atrial fibrillation, in patients with crypto-
genetic stroke usually before the implantation of a
cardiac loop ECG recording, in those with type 2 or
3 BrS, and in family members of BrS patients.
Implantable cardioverter defibrillators
The decision to perform epicardial or endocardial lead
implantation or to place the device in a thoracic or
subcostal pocket was made according to patient’s age,
anthropometric characteristics, and level of physical
activity, as previously described.9 The choice between
single-chamber and dual-chamber devices was driven by
the presence of previous episodes of supraventricular
arrhythmias or evidence of sinus node dysfunction and
patient’s activity in order to prevent inappropriate
shocks, as previously described.10 Implantable cardiover-
ter defibrillator (ICD) programming at the time of
implantation changed over time. After our initial experi-
ence, the ventricular fibrillation detection rate was
increased from 180 to more than 200 beats/min for pri-
mary prevention implantations, and a monitor zone was
added.11Conversely, in patients undergoing ICD therapy
for secondary prevention,12 a monitor zone (>150 beats/
min) and a fast VT zone (180–200 beats/min) with anti-
tachycardia pacing and shocks were programmed in all
cases, and supraventricular tachycardia discriminators
were activated if available.
Supraventricular arrhythmias, incidence and treatments
All patients were evaluated for the incidence of atrial
fibrillation and atrial flutter. We evaluated the pharma-
cological therapy and eventually the catheter ablation
treatment.13 In patients with atrial fibrillation, we
administrated anticoagulation following the CHADS2
score guidelines from 200414 and from 2012 the
CHA2DS2VASc score.
15 All patients having undergone
catheter ablation for atrial fibrillation received anti-
coagulation therapy for a minimum of 3 months
immediately after the procedure independently of
thromboembolic risk.
Electrophysiological study
Electrophysiological study (EPS) included basal mea-
surements of conduction intervals and programmed ven-
tricular stimulation, as previously reported by our group.
A patient was considered inducible if a sustained ven-
tricular arrhythmia (ventricular fibrillation, polymorphic
VT, or monomorphic VT lasting greater than 30 s or
requiring emergency intervention) was induced.16
Genetic testing was recommended to all patients with
diagnosis of BrS.
Cerebrovascular events
In detail, the diagnosis of ischemic stroke was done
according to the AHA/ASA Guidelines17 (Class I, Level
of Evidence A) using CT and angio-CT in the emergency
department. Magnetic resonance imaging was also per-
formed in all patients after the acute phase in order to
assess the specific characteristics of the ischemic lesions.
An echocolor Doppler of the carotid artery was performed
in all patients after a stroke event. Patients with stroke
related to atrial fibrillation presented cardioembolic
events. Neuroimaging findings supporting cardioembolic
stroke included simultaneous or sequential strokes in
different arterial territories. All patients also underwent
a transcranial Doppler to exclude a patent foramen ovale.
Demographic and clinical data, risk factors, presenting
symptoms, findings from brain imaging and prognosis
were retrospectively collected for each patient presenting
any cerebrovascular thromboembolic event.
Follow-up
Clinical follow-up of patients consisted of physical exam-
ination and ECG performed at least every 6 months in
case of symptomatic and device therapy patients and
every 2 years otherwise. Clinical data were regularly
collected. Follow-up of ICDs was performed at 1 and 3
months after implantation and thereafter every 6 months
in the outpatient clinic, combined with remote device
monitoring provided by the cardiac device company. All
available electrograms of appropriate and inappropriate
shocks were analysed by at least two independent inves-
tigators. Malignant ventricular arrhythmias were defined
as: sudden death or appropriate implantable cardioverter
defibrillator therapy. Atrial fibrillation was specifically
searched with 24-h Holter monitoring and implantable
loop recorder devices. The former ones were performed
every year in asymptomatic patients and every 3–6
months in symptomatic ones. The loop recorders were
implanted in those patients with palpitations and nega-
tive Holter examinations.
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Statistical analysis
Continuous variables are expressed as meanSD or
median and range as appropriate. Categorical variables
are expressed as absolute and relative frequencies. Com-
parisons of continuous variables were done with a Stu-
dent’s t-test or the Mann–Whitney U-test as appropriate.
The chi-square test or the Fisher’s exact test was used to
compare categorical variables as appropriate. A P value
less than 0.05 was considered statistically significant.
Statistical analyses were conducted using the SPSS soft-
ware (SPSS v20, Chicago, Illinois, USA).
Results
Study population
In our registry, 671 patients (age 42.1 17.0 years; men
63%) with BrS were collected; a spontaneous type 1 ST
elevation was observed in 17% of patients (n¼ 113). The
main characteristics of the study population are detailed
in Table 1. The mean follow-up after the BrS diagnosis
was 10.8 5.5 years.
Seventeen patients (3%) had aborted sudden death as
first manifestation and 194 (29%) had at least one episode
of syncope. A family history of sudden death was present
in 43% of patients (n¼ 290); history of atrial fibrillation
was also present in a considerable number of patients
(12%; n¼ 79). Genetic test was performed in 312 patients
(46%) and a genetical mutation was found in 24% of all
the tests (n¼ 74). The mean CHADS2 score and
CHA2DS2Vasc score were, respectively, 0.14 0.42 and
0.57 0.77. Specifically, 596 patients (88.8%) with BrS
had a CHADS2 score of 0, 58 patients (8.6%) presented a
score of 1, 16 patients (2.4%) presented a score of 2, and
only 1 patient (0.2%) exhibited a CHADS2 score of 3. In
terms of CHA2DS2Vasc score, 375 patients (55.9%) pre-
sented 0, 235 patients (35.0%) had 1, 41 patients (6.1%)
exhibited 2, 16 patients (2.4%) presented 3, and finally 3
and only 1 patient (0.4% and 0.1%), respectively, pre-
sented CHA2DS2Vasc scores of 4 and 5.
Atrial fibrillation
Among 671 patients with BrS included in our registry, 79
(11.8%) presented atrial fibrillation and atrial flutter. Of
them, 69 (87.3%) were paroxysmal, 7 persistent (8.9%)
and 3 permanent (3.8%). In 32 patients (40.5%), atrial
fibrillation preceded the diagnosis of BrS; the first detec-
tion of atrial fibrillation was obtained through a standard
12-lead ECG in 31 patients (39.2%), with a 24-h Holter
monitoring in 34 (43.1%), and in the Holter memory of
ICDs in 14 (17.7%). In seven of these patients (21.9%),
the subsequent diagnosis of BrS was unmasked by
sodium channel blockers, which were administered to
prevent atrial fibrillation episodes; none of these patients
actually presented TIA/stroke.
Out of 79 patients with atrial fibrillation, in 32 (40.5%),
atrial fibrillation was already known before the BrS diag-
nosis and in 47 (59.5%), atrial fibrillation was completely
asymptomatic and the diagnosis was made accidentally or
during clinical investigations after the diagnosis of BrS or
stroke. The characteristics of these two groups have been
compared in Table 2.
Thirty patients (38.0%) had a previous ICD implantation
and inappropriate shocks because of rapid atrial fibrilla-
tion were documented in nine of them (30%). The mean
age at the time of diagnosis was 46.1 15.7 years. All
patients with atrial fibrillation were treated with sotalol as
first-line medication. A total of 23 patients (29.1%) with
atrial fibrillation refractory of sotalol underwent a catheter
ablation procedure using radiofrequency or Cryoballoon
technology (6 and 17, respectively). After a mean follow-
up time of 35.0 25.4 months (median 36 months), 17
patients (73.9%) did not present any AT/atrial fibrillation
relapses after the index procedure.
Among patients with atrial fibrillation, the mean
CHADS2 score and CHA2DS2Vasc score were, respec-
tively, 0.21 0.50 and 0.65 0.88. Specifically, 65
patients (82.2%) with BrS had a CHADS2 score of 0,
11 patients (13.9%) presented a score of 1, and 3 patients
(3.8%) presented a score of 2. In terms of CHA2DS2Vasc
score, 43 patients (54.4%) presented 0, 26 patients
(32.9%) had 1, 6 patients (7.6%) exhibited 2, 3 patients
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Table 1 Study population
Age (years) 42.117.0
Sex: male 422 (63)
Spontaneous type 1 ST elevation 113 (17)
Family history of sudden death 290 (43)
ICD implantation 183 (27)
Atrial fibrillation 79 (12)
Genetic testing 312 (46)
Genetic mutationsa 74 (24)
CHADS score 0.140.42
CHA2DS2Vasc score 0.570.77
Sick sinus syndrome 16 (2)
Categorical variables are expressed as absolute and percentage (in brackets).
Continuous variables are expressed as meanSD. ICD, implantable cardioverter
defibrillator. aPercentages are calculated only among patients with genetic test.
Table 2 Comparison of patients with atrial fibrillation known before
Brugada syndrome diagnosis with those having atrial fibrillation






diagnosis (n¼47) P value
Male sex 22 (69) 30 (64) 0.8
Age (years) 44.417.4 43.616.1 0.8
Hypertension 6 (19) 7 (15) 0.8
BMI (kg/m2) 25.52.1 24.83.2 0.4
CHADS score 0.280.58 0.130.34 0.2
CHA2DS2-VASc score 0.660.94 0.600.82 0.8
Type 1 ECG pattern 5 (16) 4 (9) 0.5
Genetic mutationa 2 (6) 9 (19) 0.2
Malignant arrhythmic events 4 (12) 2 (4) 0.2
Left atrial diameter (mm) 38.15.4 38.77.3 0.8
TIA/Stroke 1 (3) 10 (21) 0.02
Categorical variables are expressed as absolute and percentage (in parentheses).
Continuous variables are expressed as meanSD. AF, atrial fibrillation; BrS,
Brugada syndrome; TIA, transient ischemic attack. aPercentages are calculated
only among patients with genetic test.
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(3.8%) presented 3, and only 1 patient (1.3%) presented a
CHA2DS2Vasc score of 4.
Cerebrovascular events
The total number of cerebrovascular events in our study
population was 13 (1.9%). Two of them (15%) were
excluded from our analysis because no clear relationship
with atrial fibrillation and embolic cause could be recog-
nized. Particularly, the first one was a 66-year-old patient
with hypertension, dyslipidaemia having experienced a
stroke in the irrigation area of the left internal carotid
artery symptomatic for aphasia and confusional state;
after having documented a 90% stenosis of the left carotid
artery, the patient underwent a successful carotid endar-
terectomy. The second one was a 71-year-old woman
having experienced a TIA after a long history of a
recurrent breast cancer treated with surgery and radio-
therapy. Interestingly, 11 patients with BrS experienced
cerebrovascular events, all related to atrial fibrillation
(13.9%); specifically, 6 of them (54.5%) presented as
cerebrovascular strokes and 5 (45.5%) as transient ische-
mic attacks. All these patients are described in Table 3.
Of note, seven of these patients (63.6%) experienced the
cerebrovascular event as the first manifestation of BrS.
None of them was under oral anticoagulation at the time
that cerebrovascular events occurred.
The clinical characteristics of patients with TIA/stroke
related to atrial fibrillation are listed in Table 3. The
mean age at presentation was 59.4 11.2 years old
(median 62 years old). Three of them (27.2%) presented
a spontaneous type 1 ECG pattern. As shown in Table 3,
the most common clinical presentation was aphasia and
speech disorders (in seven patients, 64%) and left hemi-
paresis or paralysis (in five patients, 45%). A 49-year-old
patient presented a posterior circulation infarction asso-
ciated with nausea, vertigo, presyncope and de novo
diagnosis of atrial fibrillation. Most of the patients pre-
sented a complete clinical resolution after the cerebro-
vascular events (63.6%), two of them exhibited a residual
left hemiparesis (18.2%), another one (9.1%) showed a
degenerative cognitive impairment after recurrent epi-
sodes of embolic strokes and the last one (9.1%) died 1
month and 15 days later from acute mesenterial ischemia.
Both patients were under anticoagulation therapy.
Among patients with TIA/stroke and atrial fibrillation,
nine patients (81.8%) had a CHADS2 score of 0, another
patient (9.1%) presented a score of 1 and the last one
(9.1%) exhibited a score of 2. In terms of CHA2DS2Vasc
score, five patients (45.4%) had 0, four patients (36.3%)
had 1, and two patients (9.1%), respectively, presented a
score of 2 and 3. The mean CHADS2 score and
CHA2DS2Vasc score were, respectively, 0.27 0.65 and
0.82 0.98.
As shown in Table 4, patients presenting stroke were
significantly older as compared with the age at
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presentation of those presenting atrial fibrillation and BrS
without any cerebrovascular events (59.4 11.2 vs.
43.9 16.7 years old; P¼ 0.004). Of note, CHADS2
and CHA2DS2Vasc scores did not significantly differ
between the two study groups. Although the left atrial
diameter was slightly higher in the TIA/stroke group, it
was not significantly different between the two groups
(Table 4). Figure 1 shows the distribution of CHA2DS2-
Vasc score in patients with atrial fibrillation and TIA/
stroke compared with those with atrial fibrillation without
TIA/stroke. Of note, most of the patients presenting a
cerebrovascular event exhibited a CHA2DS2Vasc score of
0 and 1 (respectively, 45 and 36%). No significant rela-
tionship was found betweenmalignant arrhythmic events
and cerebrovascular accidents during the follow-up. Sig-
nificantly, 91% of patients presenting atrial fibrillation-
related TIA/strokes had asymptomatic episodes of atrial
fibrillation, diagnosed by further clinical investigations or
recorded by ICD Holter memory, compared with 25% of
asymptomatic atrial fibrillation in patients without cere-
brovascular accidents (P< 0.0001). The diagnosis of atrial
fibrillation was obtained while checking the ICD in five
patients (45.4%), during in-hospital monitoring after the
cerebrovascular accidents in two patients (18.2%), and by
means of ECG and 24-h Holter monitoring in the remain-
ing four patients (36.4%). The other clinical character-
istics were similar in both populations.
Discussion
The present study showed that: the incidence of cardio-
embolic stroke in patients with BrS and atrial fibrillation
was unexpectedly high at 13.9%; these patients had a low
CHA2DS2Vasc score (82% of them with a score of 0 or 1),
which was similar to those patients with BrS and atrial
fibrillation without TIA/stroke; in 63.6% of patients, the
cerebrovascular accident was the first manifestation of
BrS, occurring before the diagnosis; among patients pre-
senting TIA/stroke, a significantly higher number of
asymptomatic patients was found when compared with
those without cerebrovascular events (91 vs 25%;
P< 0.0001); patients experiencing a cardioembolic
TIA/stroke were significantly older than those without
a cerebrovascular event.
The incidence of cardioembolic stroke among patients
with BrS and atrial fibrillation was unusually high,
accounting for about 14%. Of note, the CHADS2 score
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Table 4 Characteristics of patients with stroke vs. those without







Male sex 9 (82) 43 (63) 0.31
Age (years) 59.411.2 43.916.7 0.004
Hypertension 2 (18) 12 (18) 0.62
Diabetes mellitus 1 (9) 1 (1) 0.26
BMI (kg/m2) 25.13.1 24.92.5 0.81
CHADS score 0.270.65 0.130.41 0.34
CHA2DS2-VASc score 0.820.98 0.650.88 0.56
Type 1 ECG pattern 2 (18) 7 (10) 0.60
ICD presence 6 (55) 24 (35) 0.32
Genetic mutationa 1 (25) 10 (29) 0.69
Malignant arrhythmic events 1 (9) 5 (7) 0.61
Asymptomatic atrial fibrillation 10 (91) 17 (25) <0.0001
Left atrial diameter (mm) 40.12.1 38.16.9 0.35
Categorical variables are expressed as absolute and percentage (in parentheses).
Continuous variables are expressed as meanSD. ICD, implantable cardioverter
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AF with stroke
The histogram shows the distribution of CHA2DS2Vasc score in patients with atrial fibrillation and transient ischemic attack/stroke (dark grey
columns) compared with those with atrial fibrillation without transient ischemic attack/stroke (light grey columns). Interestingly, most of the patients
with atrial fibrillation presenting a cerebrovascular event exhibited a CHA2DS2Vasc score of 0 and 1 (respectively, 45 and 36%).
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and CHA2DS2Vasc scores were low both in the study
population and in those patients with atrial fibrillation.
Respectively, a CHADS2 of 0 represented 89% of all
patients and a CHA2DS2Vasc score of 0 and 1 both
constituted the 91% of the overall study population.
Similarly, patients with atrial fibrillation exhibited mean
CHADS2 and CHA2DS2Vasc scores of 0.21 0.50 and
0.65 0.88, respectively. Specifically, a CHADS2 of 0
represented 82.2% of these patients, 13.9% presented a
score of 1, and 3.8% exhibited a score of 2. A CHA2DS2-
Vasc score of 0 and 1 both constituted the 87% of all
patients with BrS and atrial fibrillation; only 7.6% exhib-
ited a CHA2DS2Vasc score of 2, 3.8% presented 3, and
only 1.3% presented a CHA2DS2Vasc score of 4. As Fig. 1
shows, patients with atrial fibrillation-related cardioem-
bolic event exhibited a similar distribution in CHADS2
and CHA2DS2Vasc scores; most of them exhibited a
theoretically low profile risk for thromboembolic events
at the time TIA/stroke occurred (81.8% of them pre-
sented both a CHADS2 of 0 and a CHA2DS2Vasc score of
0/1). Only two patients (18.2%) in the group of atrial
fibrillation and TIA/stroke had, respectively, a CHADS2
at least 1 and a CHA2DS2Vasc score at least 2. These
findings highlighted that CHADS2 and CHA2DS2Vasc
scores did not correlate with a higher risk of thromboem-
bolic events in the specific subset of BrS patients with
atrial fibrillation, in contrast with literature data on the
general population.13,14,18 In fact, the annual adjusted
stroke rate has been reported to be 1.9% for patients with
CHADS2 of 0, 2.8% for those with CHADS2 of 1, 4.0% for
those with CHADS2 of 2.
18 Similarly, the annual adjusted
stroke rate has been reported to be 0% for patients with
CHA2DS2Vasc score of 0, 1.3% for those with CHA2DS2-
Vasc score of 1, 2.2% for those with CHA2DS2Vasc score
of 2, and 3.2% for those having a CHA2DS2Vasc score of
3.18 Conversely to the literature data reporting high
reliability of CHADS2 and CHA2DS2Vasc scores for
predicting cerebrovascular accidents on the general pop-
ulation presenting atrial fibrillation, these scores do not
seem to adequately predict the occurrence of cardioem-
bolic events in patients with BrS and atrial fibrillation.
Of note, in 7 out of 11 patients (63.6%), the cerebrovas-
cular accident was the presenting manifestation, occur-
ring before the diagnosis of BrS. This might suggest that a
cardioembolic cryptogenic TIA/stroke should raise the
suspicion of atrial fibrillation episodes possibly associated
with underlying BrS, especially in younger patients.
Interestingly, most of the patients having experienced
TIA/stroke had asymptomatic episodes of atrial fibrilla-
tion (91%) in contrast with those without cerebrovascular
events who presented only 25% of asymptomatic atrial
fibrillation. An unrecognized atrial fibrillation might
hypothetically result in higher risk of thromboembolic
events because neither antiarrhythmic nor anticoagula-
tion therapies have the chance to be introduced in these
patients. As the incidence of atrial fibrillation in patients
with BrS has been reported in a considerable number of
BrS patients1–5 and the overall prevalence of asymptom-
atic episodes in our study population is considerably high
(34%), especially in those presenting TIA/stroke (91%),
the use of more invasive diagnostic tools, such as loop
recorder implantation might be hypothetically consid-
ered in this specific group of patients in order to increase
the rate of atrial fibrillation detection. As a matter of fact,
previous studies have shown that prolonged and contin-
uous rhythm monitoring are able to critically improve the
detection of silent episodes of atrial fibrillation.19–21
Implantable subcutaneous cardiac monitors and external
loop recorders have been demonstrated to be effective in
the early detecting of atrial tachyarrhythmias by avoiding
delays in the therapy evaluation.22–24 Specifically, a
recent prospective and randomized study showed that
a 3-year monitoring by insertable cardiac monitors in
cryptogenic stroke patients resulted in a significantly
higher atrial fibrillation detection rate compared with
routine care.24 Given the frequency of asymptomatic first
episodes and the long median time to detection, the
authors concluded highlighting the limitations of the
traditional atrial fibrillation detection methods.
Moreover, as the CHADS2 and CHA2DS2Vasc scores do
not predict cerebrovascular events in patients with BrS
and atrial fibrillation, the anticoagulation strategy should
not be based anymore on such scores and should be
theoretically revised for this specific subset of patients.
However, our findings have to be confirmed by further
larger, prospective studies. Of note, in our study, the
pharmacologic therapy of those patients with atrial fibril-
lation and BrS was based on sotalol. However, in litera-
ture, also hydroquinidine has been proven to be effective
and safe in preventing recurrences of atrial fibrillation and
atrial flutter in patients with Brugada pattern.6
Interestingly, those patients experiencing a cardioem-
bolic TIA/stroke were significantly older than those
without a cerebrovascular event (59.4 11.2 vs.
43.9 16.7, P¼ 0.004); thus, the age seems to be associ-
ated with a higher risk for developing cerebrovascular
embolic accidents. No other characteristics were found to
be significantly associated with higher thromboembolic
risk. However, larger and prospective studies would be
needed to confirm our findings and possibly find further
predictors of cardioembolic TIA/stroke in this specific
population.
Limitations
Some limitations can be found in our study. The present
work is a retrospective and single-centre study. More-
over, as the number of cerebrovascular events was rela-
tively small (n¼ 11), multivariate analysis and Kaplan–
Meier curves were not performed. As patients with a
negative CT and a clinical diagnosis of TIA were planned
for elective magnetic resonance imaging and these
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further examinations were then performed in other cen-
ters, we were not able to achieve the information about
MRI.
A prospective study, directly involving also the Neuro-
logical Department, to assess, on one hand, the incidence
of Brugada pattern among patients with stroke and, on
the other hand, the incidence of stroke among patients
with a previous diagnosis of Brugada pattern would be
desirable.
Conclusion
The current study documented an unusually high inci-
dence of cerebral embolism events in patients with BrS
and atrial fibrillation as compared with the expected
incidence using current scores. The reason for this abnor-
mal high incidence of thromboembolism events is
unclear. Because of the many asymptomatic episodes
of atrial fibrillation in this population, active monitoring
(ICD remote monitoring, implantable loop recording)
may be justified.
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